Global

Veterinary Sciences Experts

Widmann Rudolf

Chief Executive Officer
Veterinary Science
Veterinary Sciences
Sweden

Biography

Dr. Rudolf Widman achieved a long-cherished goal in establishing AOP Orphan. His interest in rare diseases dates back to his pharmacy studies at the University of Innsbruck, which he completed in 1981. He deepened his knowledge in the course of writing his dissertation and working as an assistant at the Institute for Pharmacology in Innsbruck, focusing particularly on epilepsy and affections of the central nervous system. In the years that followed, he worked at the Max Planck Institute for neurological research on cerebral infarction. In 1991, he entered the private sector and began his career in quality management in IMMUNO. Two years later, he joined Wellcome Austria Pharma, where he worked as Head of Medical Services until the company was taken over by Glaxo. In the new company Glaxo-Wellcome, he was active in the Business Unit Hospital as Senior Medical Marketing Adviser. It was during his time in the international pharmaceutical industry that he realized that the large companies were not concentrating on rare diseases and that patients were often being left stranded. This ultimately led to him founding AOP Orphan in 1996, where he is both owner and CEO. Dr. Rudolf Widman achieved a long-cherished goal in establishing AOP Orphan. His interest in rare diseases dates back to his pharmacy studies at the University of Innsbruck, which he completed in 1981. He deepened his knowledge in the course of writing his dissertation and working as an assistant at the Institute for Pharmacology in Innsbruck, focusing particularly on epilepsy and affections of the central nervous system. In the years that followed, he worked at the Max Planck Institute for neurological research on cerebral infarction. In 1991, he entered the private sector and began his career in quality management in IMMUNO. Two years later, he joined Wellcome Austria Pharma, where he worked as Head of Medical Services until the company was taken over by Glaxo. In the new company Glaxo-Wellcome, he was active in the Business Unit Hospital as Senior Medical Marketing Adviser. It was during his time in the international pharmaceutical industry that he realized that the large companies were not concentrating on rare diseases and that patients were often being left stranded. This ultimately led to him founding AOP Orphan in 1996, where he is both owner and CEO.

Research Interest

Veterinary and Veterinary Science

Global Experts from Sweden

Global Experts in Subject

Share This Profile
Recent Expert Updates
  • Matthew L Stone
    Matthew L Stone
    pediatrics
    University of Virginia Health System; Charlottesville, VA
    United States of America
  • Dr.   Matthew
    Dr. Matthew
    pediatrics
    University of Virginia Health System; Charlottesville, VA
    United States of America
  • Dr.  L Stone Matthew
    Dr. L Stone Matthew
    pediatrics
    University of Virginia Health System; Charlottesville, VA
    United States of America
  • Dr.  L Stone
    Dr. L Stone
    pediatrics
    University of Virginia Health System; Charlottesville, VA
    United States of America
  • Dr. Matthew L Stone
    Dr. Matthew L Stone
    pediatrics
    University of Virginia Health System; Charlottesville, VA
    United States of America
  • Dr.  R Sameh
    Dr. R Sameh
    pediatrics
    King Abdul Aziz University
    United Arab Emirates
  • Dr.   R Ismail,
    Dr. R Ismail,
    pediatrics
    King Abdul Aziz University
    United Arab Emirates
  • Sameh R Ismail,
    Sameh R Ismail,
    pediatrics
    King Abdul Aziz University
    United Arab Emirates
  • Dr.   Sameh R Ismail,
    Dr. Sameh R Ismail,
    pediatrics
    King Abdul Aziz University
    United Arab Emirates
  • Dr.   William
    Dr. William
    pediatrics
    Maimonides Medical Center
    United States of America